Orchestra Cash from 2010 to 2024

OBIO Stock   5.68  0.11  1.97%   
Orchestra BioMed Cash yearly trend continues to be very stable with very little volatility. Cash is likely to drop to about 22.2 M. Cash is the total amount of money in the form of currency that Orchestra BioMed Holdings has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2010-12-31
Previous Quarter
30.6 M
Current Value
22.2 M
Quarterly Volatility
3.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Orchestra BioMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Orchestra BioMed's main balance sheet or income statement drivers, such as Net Interest Income of 4 M, Interest Income of 4 M or Depreciation And Amortization of 227.4 K, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or PTB Ratio of 4.68. Orchestra financial statements analysis is a perfect complement when working with Orchestra BioMed Valuation or Volatility modules.
  
Check out the analysis of Orchestra BioMed Correlation against competitors.

Latest Orchestra BioMed's Cash Growth Pattern

Below is the plot of the Cash of Orchestra BioMed Holdings over the last few years. Cash refers to the most liquid asset of Orchestra BioMed Holdings, which is listed under current asset account on Orchestra BioMed Holdings balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Orchestra BioMed customers. The amounts must be unrestricted with restricted cash listed in a different Orchestra BioMed account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Orchestra BioMed's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Orchestra BioMed's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Pretty Stable
   Cash   
       Timeline  

Orchestra Cash Regression Statistics

Arithmetic Mean20,415,040
Geometric Mean20,005,110
Coefficient Of Variation19.25
Mean Deviation1,586,736
Median20,343,000
Standard Deviation3,929,823
Sample Variance15.4T
Range20.6M
R-Value0.12
Mean Square Error16.4T
R-Squared0.01
Significance0.67
Slope106,004
Total Sum of Squares216.2T

Orchestra Cash History

202422.2 M
202330.6 M
202219.8 M
20219.9 M

Other Fundumenentals of Orchestra BioMed Holdings

Orchestra BioMed Cash component correlations

About Orchestra BioMed Financial Statements

Orchestra BioMed investors utilize fundamental indicators, such as Cash, to predict how Orchestra Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

Pair Trading with Orchestra BioMed

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.

Moving against Orchestra Stock

  0.32A Agilent Technologies Sell-off TrendPairCorr
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Orchestra BioMed Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Orchestra BioMed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Orchestra Biomed Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Orchestra Biomed Holdings Stock:
Check out the analysis of Orchestra BioMed Correlation against competitors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.60)
Revenue Per Share
0.073
Quarterly Revenue Growth
1.356
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.